Scandion Oncology A/S
A biotech company under liquidation that developed cancer drug resistance therapies.
SCOL | ST
Overview
Corporate Details
- ISIN(s):
- DK0061031895 (+3 more)
- LEI:
- 549300MPWDMQ5LZEGD09
- Country:
- Denmark
- Address:
- Fruebjergvej 3, 2100 København Ø
- Website:
- https://scandiononcology.com/
Description
Scandion Oncology A/S is a biotechnology company currently under liquidation. Prior to this, it operated as a clinical-stage firm focused on developing therapies to overcome cancer drug resistance. The company's primary objective was to develop first-in-class, oral add-on drugs designed to reverse resistance and enhance the efficacy of existing cancer treatments. Its lead compound was SCO-101, which was investigated in clinical trials for its potential to restore the effectiveness of chemotherapy in patients with various types of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Scandion Oncology A/S filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Scandion Oncology A/S
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Scandion Oncology A/S via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
